Pharmaceutical News

RSS

Vertex Pharmaceuticals completes acquisition of ViroChem Pharma

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), completed its acquisition today of ViroChem Pharma Inc., a privately-held company with two investigational HCV polymerase inhibitors in clinical development.

12 Mar 2009

New drug derived from magnolia trees proves safe, tolerable in preventing blood clots

A new drug derived from magnolia trees appears to be able to uncouple two important functions of thrombin in blood clot formation and may offer a way to better control the potentially dangerous complications of bleeding and clot formation during procedures to open blocked coronary arteries, say researchers at the Duke Clinical Research Institute (DCRI).

12 Mar 2009

Discovery may lead to immunosuppressant drugs that have fewer adverse side effects

Immunosuppressive treatment is necessary to prevent rejection of an organ after transplant and has great potential for treating chronic inflammatory diseases.

12 Mar 2009

Oncolytics Biotech (TSX:ONC, NASDAQ:ONCY) starts U.S. enrolment in trial for non-small cell lung cancer patients

Oncolytics Biotech Inc. has announced that it has started patient enrolment in a Phase 2 clinical trial using intravenous administration of Reolysin in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours.

12 Mar 2009

DSM obtains exclusive world-wide license for innovative drug delivery technology

Royal DSM N.V. has announced that DSM Biomedical obtained an exclusive world-wide license for a unique drug & biologic delivery system developed by MediVas LLC, a San Diego based biomedical company.

12 Mar 2009

Roche (SWX: ROG.VX; RO.S) and Genentech (NYSE:DNA) agree to combine

Roche and Genentech announced today that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US$95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche.

12 Mar 2009

Novel anti-inflammatory therapy protects lungs from runaway inflammation

A novel anti-inflammatory therapy designed by Vanderbilt University Medical Center investigators prevents acute lung injury in mice exposed to an inflammation-causing toxin, the researchers report in the journal Molecular Therapy.

11 Mar 2009

Tissue-cultured smallpox vaccine shows promise

Administration of a tissue-cultured smallpox vaccine showed signs of an effective vaccine response with no serious adverse events, according to a study in the March 11 issue of JAMA, the Journal of the American Medical Association.

11 Mar 2009

Eli Lilly granted temporary restraining order to halt launch of generic Raloxifene

Eli Lilly and Company has issued the following statement after being granted a temporary restraining order to halt the launch of a generic version of Evista (raloxifene HCl tablets) by Teva Pharmaceuticals.

11 Mar 2009

Immune-based therapy approved in Europe for pediatric cancer patients

The European Commission, which oversees legislation and regulation for the European Union, has approved a therapy for pediatric patients with non-metastatic, resectable osteosarcoma, a type of bone cancer.

11 Mar 2009

A vaccine for multiple sclerosis

Apitope Technology Ltd is a biopharmaceutical company that specialises in developing treatments for allergy and autoimmune diseases.

11 Mar 2009

CytoDyn responds to FDA as high court rules agency cannot guarantee drug safety

CytoDyn, Inc. has sent the FDA what the Company believes is a complete response to the agency's preliminary comments on Cytolin, a monoclonal antibody designed to restore immune function in those afflicted with HIV/AIDS.

10 Mar 2009

Azaya Therapeutics selected for Nanotechnology Characterization Lab by National Cancer Institute

Azaya Therapeutics, Inc. has announced that it has been selected by the National Cancer Institute (NCI) for a research collaboration to study Azaya's lead cancer therapy, ATI - 1123.

10 Mar 2009

Ranbaxy secures FDA approval for quinapril hydrochloride + hydrochlorothiazide tablets

Ranbaxy Pharmaceuticals has announced approval from the U.S. Food and Drug Administration to manufacture and market Quinapril Hydrochloride & Hydrochlorothiazide (Quinapril + HCTZ) Tablets, 10mg/12.5mg, 20mg/12.5mg and 20mg/25mg.

5 Mar 2009

European Commission and US FDA approve intravenous formulation of temozolomide

Schering-Plough Corporation (NYSE:SGP) today announced that the European Commission and the US FDA both approved the intravenous (IV) formulation of temozolomide as an alternative to the already approved oral form of the drug.

5 Mar 2009

Pharmacies offering no-cost antibiotics should promote responsible use, CDC says

CDC last week sent out letters to several chain pharmacies that offer no-cost prescription antibiotics to low-income consumers urging them to promote responsible use of antibiotics, the New York Times reports.

5 Mar 2009

Dorgan, McCain, Snowe introduce bill to allow prescription drug reimportation

Sens. Byron Dorgan (D-N.D.), John McCain (R-Ariz.) and Olympia Snowe (R-Maine) on Wednesday introduced a bill (S 525) that would allow the reimportation of lower-cost prescription drugs from other nations, Bloomberg reports.

5 Mar 2009

Supreme Court rules against Wyeth in pre-emption case

The U.S. Supreme Court on Wednesday ruled 6-3 that consumers harmed by an FDA-approved pharmaceutical product can sue the drugmaker for liability in state courts, the San Francisco Chronicle reports (Egelko, San Francisco Chronicle, 3/5).

5 Mar 2009

FDA warning on risk of wearing medicated patches during MRIs

Certain adhesive patches that deliver medication through the skin have been found to be a risk to patient safety. The patches, if worn while undergoing magnetic resonance imaging scans or MRIs, can cause skin burns, says the U.S. Food and Drug Administration today.

5 Mar 2009

Off-label drug uses wasting millions, raising health risks

A recent study in Oregon suggests that drugs designed for treating the most severe mental illnesses are often prescribed at inappropriately low doses and at considerable expense, for use in conditions where their benefit has not been established.

4 Mar 2009

Pharmaceutical News

Vertex Pharmaceuticals completes acquisition of ViroChem Pharma

New drug derived from magnolia trees proves safe, tolerable in preventing blood clots

Discovery may lead to immunosuppressant drugs that have fewer adverse side effects

Oncolytics Biotech (TSX:ONC, NASDAQ:ONCY) starts U.S. enrolment in trial for non-small cell lung cancer patients

DSM obtains exclusive world-wide license for innovative drug delivery technology

Roche (SWX: ROG.VX; RO.S) and Genentech (NYSE:DNA) agree to combine

Novel anti-inflammatory therapy protects lungs from runaway inflammation

Tissue-cultured smallpox vaccine shows promise

Eli Lilly granted temporary restraining order to halt launch of generic Raloxifene

Immune-based therapy approved in Europe for pediatric cancer patients

A vaccine for multiple sclerosis

CytoDyn responds to FDA as high court rules agency cannot guarantee drug safety

Azaya Therapeutics selected for Nanotechnology Characterization Lab by National Cancer Institute

Ranbaxy secures FDA approval for quinapril hydrochloride + hydrochlorothiazide tablets

European Commission and US FDA approve intravenous formulation of temozolomide

Pharmacies offering no-cost antibiotics should promote responsible use, CDC says

Dorgan, McCain, Snowe introduce bill to allow prescription drug reimportation

Supreme Court rules against Wyeth in pre-emption case

FDA warning on risk of wearing medicated patches during MRIs

Off-label drug uses wasting millions, raising health risks

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News